Aim To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by the Italian National Health System (NHS) for patients who will be newly diagnosed through active HCV screening, implemented in Italy from 2020. Methods A previously published Markov model was used to estimate the disease complications avoided and the associated savings over 20 years to treat a standardised population of 10,000 HCV-infected patients diagnosed as a result of screening. Disease progression probabilities and fibrosis stage distribution were based on previously reported data in the literature. Real-life treatment effectiveness and medical expenses for disease management were estimated starting from a representative cohort of HCV...
To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by th...
OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in ...
Objective: We estimated the cost consequence of Italian National Health System (NHS) investment in d...
Aim To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment b...
To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by th...
OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in ...
Objective: We estimated the cost consequence of Italian National Health System (NHS) investment in d...
Aim To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment b...
To evaluate the cost-consequences of the investment for anti-hepatitis C virus (HCV) treatment by th...
OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in ...
Objective: We estimated the cost consequence of Italian National Health System (NHS) investment in d...